IVERIC bio, Inc. (NASDAQ:ISEE) Expected to Post FY2025 Earnings of $0.34 Per Share

IVERIC bio, Inc. (NASDAQ:ISEE) – Wedbush issued their FY2025 EPS estimates for shares of IVERIC bio in a research report issued on Sunday, June 20th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of $0.34 per share for the year.

Separately, Zacks Investment Research raised IVERIC bio from a “sell” rating to a “hold” rating in a research report on Tuesday, May 11th.

ISEE opened at $5.98 on Tuesday. IVERIC bio has a 12-month low of $3.97 and a 12-month high of $7.98. The firm has a market capitalization of $539.22 million, a PE ratio of -5.20 and a beta of 1.68. The company has a 50 day simple moving average of $6.57.

IVERIC bio (NASDAQ:ISEE) last posted its quarterly earnings results on Tuesday, May 4th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.04).

In other IVERIC bio news, EVP Pravin Dugel sold 28,301 shares of IVERIC bio stock in a transaction on Monday, April 5th. The stock was sold at an average price of $6.34, for a total value of $179,428.34. Following the completion of the transaction, the executive vice president now directly owns 50,000 shares of the company’s stock, valued at approximately $317,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in shares of IVERIC bio by 4.4% in the 1st quarter. BlackRock Inc. now owns 7,059,634 shares of the company’s stock valued at $43,628,000 after purchasing an additional 295,366 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of IVERIC bio by 2.3% in the 1st quarter. Perceptive Advisors LLC now owns 4,585,512 shares of the company’s stock valued at $28,338,000 after purchasing an additional 102,799 shares during the last quarter. Yiheng Capital Management L.P. increased its stake in shares of IVERIC bio by 1,665.7% in the 1st quarter. Yiheng Capital Management L.P. now owns 2,784,083 shares of the company’s stock valued at $17,206,000 after purchasing an additional 2,626,407 shares during the last quarter. Frazier Management LLC increased its stake in shares of IVERIC bio by 2.0% in the 1st quarter. Frazier Management LLC now owns 2,544,500 shares of the company’s stock valued at $15,725,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of IVERIC bio by 0.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,163,192 shares of the company’s stock valued at $13,369,000 after purchasing an additional 9,520 shares during the last quarter. 88.99% of the stock is owned by hedge funds and other institutional investors.

About IVERIC bio

IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Further Reading: Trading Strategy Methods for Individual Investors

Earnings History and Estimates for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.